|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0001 - 0.0003|
|52 Week Range||0.0001 - 0.9100|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (BRTX), a life sciences company focused on stem cell-based therapies, announced today feature coverage in the news outlet, IEEE Pulse, a magazine of the IEEE Engineering in Medicine and Biology Society. To view the IEEE Pulse Magazine’s article featuring BioRestorative, click here.
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Israeli Patent Office has issued BioRestorative a Notice of Allowance on its patent application for a method of generating brown fat stem cells. This is the eighth patent issued, in the United States and other countries, for the Company’s brown fat technology related to BioRestorative’s metabolic program (ThermoStem® Program).
This is the second patent issued for the Company’s brown fat technology in Australia and adds to three other patents related to BioRestorative’s metabolic program (ThermoStem® Program) that have previously been issued to the Company in the United States and other countries. This patent will allow for the protection of a specific isolated human brown adipose tissue stem cell line capable of differentiating into multiple cell types.
BioRestorative Therapies, Inc. (the “Company") (BRTX), a life sciences company focused on stem cell-based therapies, today announced that a member of the Company’s Scientific Advisory Board and its Clinical Director of Regenerative Disc/Spine Program, Wayne J. Olan, MD, has received the Distinguished Alumni Award for Achievement from the Chicago Medical School (“CMS”). The award is bestowed upon CMS alumni who have made a significant impact in the field of medicine and whose efforts have brought distinction to the Chicago Medical School. Dr. Olan’s achievements will be celebrated at the CMS Alumni Dinner and Awards Ceremony on Saturday, October 5, 2019 as part of the CMS Reunion Weekend in Chicago.
MELVILLE, N.Y., Sept. 13, 2019 -- BioRestorative Therapies, Inc. (the “Company") (OTC: BRTX), a life sciences company focused on stem cell - based therapies, is providing.
PCOS is difficult to manage and the current standard of care, including lifestyle changes and multi-line medications, may be moderately effective and unable to address long-term risks of type 2 diabetes, cardiovascular disease and psychiatric problems. The Company hopes that its novel platform technology, using brown adipose derived stem cells, will become an emerging therapy for PCOS.
BioRestorative Therapies, Inc. (the “Company") (BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has entered into a securities purchase agreement with Arena Investors LP (“Arena”). The agreement provides for the issuance and sale to Arena of 5,500,000 shares of Series A preferred stock of the Company, a warrant for the purchase of 6,000,000 shares of common stock of the Company and a convertible promissory note of the Company in the principal amount of $500,000 for an aggregate purchase price of $5,400,000. Additional details regarding the private placement will be included in a Form 8-K filed by the Company with the Securities and Exchange Commission.
BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (BRTX), a life sciences company focused on stem cell-based therapies, today announced that Francisco Silva, Vice President of Research and Development, will present at the 2019 American Society of Gene and Cell Therapy (ASGCT) to be held April 29 – May 2, 2019 in Washington D.C. Mr. Silva will provide an update on BioRestorative’s ThermoStem® program targeted for treating metabolic disorders. This conference is the sector’s premiere forum bringing together senior executives and top decision makers in the industry within the scientific community with the shared goal of advancing and translating cutting-edge research into revolutionary treatments and cures.